201 related articles for article (PubMed ID: 35917833)
1. Artificial intelligence (AI)-based decision support improves reproducibility of tumor response assessment in neuro-oncology: An international multi-reader study.
Vollmuth P; Foltyn M; Huang RY; Galldiks N; Petersen J; Isensee F; van den Bent MJ; Barkhof F; Park JE; Park YW; Ahn SS; Brugnara G; Meredig H; Jain R; Smits M; Pope WB; Maier-Hein K; Weller M; Wen PY; Wick W; Bendszus M
Neuro Oncol; 2023 Mar; 25(3):533-543. PubMed ID: 35917833
[TBL] [Abstract][Full Text] [Related]
2. Automated quantitative tumour response assessment of MRI in neuro-oncology with artificial neural networks: a multicentre, retrospective study.
Kickingereder P; Isensee F; Tursunova I; Petersen J; Neuberger U; Bonekamp D; Brugnara G; Schell M; Kessler T; Foltyn M; Harting I; Sahm F; Prager M; Nowosielski M; Wick A; Nolden M; Radbruch A; Debus J; Schlemmer HP; Heiland S; Platten M; von Deimling A; van den Bent MJ; Gorlia T; Wick W; Bendszus M; Maier-Hein KH
Lancet Oncol; 2019 May; 20(5):728-740. PubMed ID: 30952559
[TBL] [Abstract][Full Text] [Related]
3. Updated Response Assessment in Neuro-Oncology (RANO) for Gliomas.
Youssef G; Wen PY
Curr Neurol Neurosci Rep; 2024 Feb; 24(2):17-25. PubMed ID: 38170429
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of Standard Response Assessment in Neuro-Oncology, Modified Response Assessment in Neuro-Oncology, and Immunotherapy Response Assessment in Neuro-Oncology in Newly Diagnosed and Recurrent Glioblastoma.
Youssef G; Rahman R; Bay C; Wang W; Lim-Fat MJ; Arnaout O; Bi WL; Cagney DN; Chang YS; Cloughesy TF; DeSalvo M; Ellingson BM; Flood TF; Gerstner ER; Gonzalez Castro LN; Guenette JP; Kim AE; Lee EQ; McFaline-Figueroa JR; Potter CA; Reardon DA; Huang RY; Wen PY
J Clin Oncol; 2023 Jun; 41(17):3160-3171. PubMed ID: 37027809
[TBL] [Abstract][Full Text] [Related]
5. Evaluating automated longitudinal tumor measurements for glioblastoma response assessment.
Suter Y; Notter M; Meier R; Loosli T; Schucht P; Wiest R; Reyes M; Knecht U
Front Radiol; 2023; 3():1211859. PubMed ID: 37745204
[TBL] [Abstract][Full Text] [Related]
6. RANO 2.0: Update to the Response Assessment in Neuro-Oncology Criteria for High- and Low-Grade Gliomas in Adults.
Wen PY; van den Bent M; Youssef G; Cloughesy TF; Ellingson BM; Weller M; Galanis E; Barboriak DP; de Groot J; Gilbert MR; Huang R; Lassman AB; Mehta M; Molinaro AM; Preusser M; Rahman R; Shankar LK; Stupp R; Villanueva-Meyer JE; Wick W; Macdonald DR; Reardon DA; Vogelbaum MA; Chang SM
J Clin Oncol; 2023 Nov; 41(33):5187-5199. PubMed ID: 37774317
[TBL] [Abstract][Full Text] [Related]
7. Taming Glioblastoma in "Real Time": Integrating Multimodal Advanced Neuroimaging/AI Tools Towards Creating a Robust and Therapy Agnostic Model for Response Assessment in Neuro-Oncology.
de Godoy LL; Chawla S; Brem S; Mohan S
Clin Cancer Res; 2023 Jul; 29(14):2588-2592. PubMed ID: 37227179
[TBL] [Abstract][Full Text] [Related]
8. Refinement of response assessment in neuro-oncology (RANO) using non-enhancing lesion type and contrast enhancement evolution pattern in IDH wild-type glioblastomas.
Moon HH; Kim HS; Park JE; Kim YH; Kim JH
BMC Cancer; 2021 Jun; 21(1):654. PubMed ID: 34074252
[TBL] [Abstract][Full Text] [Related]
9. Classification of High-Grade Glioma into Tumor and Nontumor Components Using Support Vector Machine.
Blumenthal DT; Artzi M; Liberman G; Bokstein F; Aizenstein O; Ben Bashat D
AJNR Am J Neuroradiol; 2017 May; 38(5):908-914. PubMed ID: 28385884
[TBL] [Abstract][Full Text] [Related]
10. Response Assessment in Pediatric Neuro-Oncology: Implementation and Expansion of the RANO Criteria in a Randomized Phase II Trial of Pediatric Patients with Newly Diagnosed High-Grade Gliomas.
Jaspan T; Morgan PS; Warmuth-Metz M; Sanchez Aliaga E; Warren D; Calmon R; Grill J; Hargrave D; Garcia J; Zahlmann G
AJNR Am J Neuroradiol; 2016 Sep; 37(9):1581-7. PubMed ID: 27127006
[TBL] [Abstract][Full Text] [Related]
11. Response Assessment in Neuro-Oncology criteria, contrast enhancement and perfusion MRI for assessing progression in glioblastoma.
Tensaouti F; Khalifa J; Lusque A; Plas B; Lotterie JA; Berry I; Laprie A; Cohen-Jonathan Moyal E; Lubrano V
Neuroradiology; 2017 Oct; 59(10):1013-1020. PubMed ID: 28842741
[TBL] [Abstract][Full Text] [Related]
12. Updated response assessment criteria for high-grade glioma: beyond the MacDonald criteria.
Sharma M; Juthani RG; Vogelbaum MA
Chin Clin Oncol; 2017 Aug; 6(4):37. PubMed ID: 28841799
[TBL] [Abstract][Full Text] [Related]
13. Response assessment of bevacizumab in patients with recurrent malignant glioma using [18F]Fluoroethyl-L-tyrosine PET in comparison to MRI.
Galldiks N; Rapp M; Stoffels G; Fink GR; Shah NJ; Coenen HH; Sabel M; Langen KJ
Eur J Nucl Med Mol Imaging; 2013 Jan; 40(1):22-33. PubMed ID: 23053325
[TBL] [Abstract][Full Text] [Related]
14. Feasibility of deep learning-based tumor segmentation for target delineation and response assessment in grade-4 glioma using multi-parametric MRI.
Hannisdal MH; Goplen D; Alam S; Haasz J; Oltedal L; Rahman MA; Rygh CB; Lie SA; Lundervold A; Chekenya M
Neurooncol Adv; 2023; 5(1):vdad037. PubMed ID: 37152808
[TBL] [Abstract][Full Text] [Related]
15. Response assessment in neuro-oncology.
Quant EC; Wen PY
Curr Oncol Rep; 2011 Feb; 13(1):50-6. PubMed ID: 21086192
[TBL] [Abstract][Full Text] [Related]
16. Volumetric assessment of tumor size changes in pediatric low-grade gliomas: feasibility and comparison with linear measurements.
D'Arco F; O'Hare P; Dashti F; Lassaletta A; Loka T; Tabori U; Talenti G; Thust S; Messalli G; Hales P; Bouffet E; Laughlin S
Neuroradiology; 2018 Apr; 60(4):427-436. PubMed ID: 29383433
[TBL] [Abstract][Full Text] [Related]
17. AI-based Virtual Synthesis of Methionine PET from Contrast-enhanced MRI: Development and External Validation Study.
Takita H; Matsumoto T; Tatekawa H; Katayama Y; Nakajo K; Uda T; Mitsuyama Y; Walston SL; Miki Y; Ueda D
Radiology; 2023 Aug; 308(2):e223016. PubMed ID: 37526545
[TBL] [Abstract][Full Text] [Related]
18. Comparison of 2D (RANO) and volumetric methods for assessment of recurrent glioblastoma treated with bevacizumab-a report from the BELOB trial.
Gahrmann R; van den Bent M; van der Holt B; Vernhout RM; Taal W; Vos M; de Groot JC; Beerepoot LV; Buter J; Flach ZH; Hanse M; Jasperse B; Smits M
Neuro Oncol; 2017 Jun; 19(6):853-861. PubMed ID: 28204639
[TBL] [Abstract][Full Text] [Related]
19. Response Assessment in Neuro-Oncology Criteria and Clinical Endpoints.
Huang RY; Wen PY
Magn Reson Imaging Clin N Am; 2016 Nov; 24(4):705-718. PubMed ID: 27742111
[TBL] [Abstract][Full Text] [Related]
20. Deep learning automates bidimensional and volumetric tumor burden measurement from MRI in pre- and post-operative glioblastoma patients.
Nalepa J; Kotowski K; Machura B; Adamski S; Bozek O; Eksner B; Kokoszka B; Pekala T; Radom M; Strzelczak M; Zarudzki L; Krason A; Arcadu F; Tessier J
Comput Biol Med; 2023 Mar; 154():106603. PubMed ID: 36738710
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
